G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company's first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. Show more

Location: 700 Park Offices Drive, Suite 200, North Carolina, 27709, US | Website: www.g1therapeutics.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$7.15

Open

$7.15

Volume

N/A

Day Range

$7.15 - $7.15

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

10.92%

Institutional Own.

54.62%

Qtr Updated

06/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
COSELA™ Trilaciclib (G1T28) (CDK4/6 inhibitor) Details Cancer, Solid tumor/s, Small cell lung cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trilaciclib (Cosela) (CDK4/6 inhibitor) Details Breast cancer, Cancer, Triple-negative breast cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trilaciclib (Cosela) (CDK4/6 inhibitor) + avelumab Details Solid tumor/s, Cancer, Bladder cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trilaciclib (Cosela) + Trodelvy® (sacituzumab govitecan-hziy) (ADC) Details Solid tumor/s, Cancer, Metastatic breast cancer, Triple-negative breast cancer , Breast cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trilaciclib (Cosela) (CDK4/6 inhibitor) Details Solid tumor/s	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rintodestrant + palbociclib Details Breast cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trilaciclib (Cosela) (CDK4/6 inhibitor) Details Colorectal cancer , Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trilaciclib (Cosela) (CDK4/6 inhibitor) Details Cancer, Non-small cell lung carcinoma, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.